aDepartment of Internal Medicine I, German Center for Infection Research, University of Bonn, Bonn bMedical Center for Infectious Diseases (MIB), Berlin cPraxis am Ebertplatz, Cologne dCenter for HIV and Hepatogastroenterology, Duesseldorf eICH, Hamburg, Germany. *Benjamin Krämer and Hans Dieter Nischalke contributed equally to the writing of this article.
AIDS. 2013 Nov 13;27(17):2817-9. doi: 10.1097/01.aids.0000433234.78807.54.
The IFNL4 ss469415590 polymorphism has recently be shown to better predict treatment response in chronic hepatitis than the IL28B rs12979860 variant. However, no data exist in patients with HIV/hepatitis C virus (HCV) coinfection. Analysing 206 HCV(+)/HIV(+) and 162 HCV(+)/HIV(-) patients, we found that compared with IL28B rs12979860, IFNL4 ss469415590 was strongly associated with response to interferon/ribavirin therapy in HCV(+)/HIV(-) individuals but not in HIV(+)/HCV(+) patients. Thus, effects of the IFNL4 variant may differ in HIV(+) and HIV(-) patients.
IFNL4 ss469415590 多态性最近被证明比 IL28B rs12979860 变异更能预测慢性乙型肝炎的治疗反应。然而，在 HIV/丙型肝炎病毒 (HCV) 合并感染患者中尚无相关数据。本研究分析了 206 例 HCV(+)/HIV(+)和 162 例 HCV(+)/HIV(-)患者，发现与 IL28B rs12979860 相比，IFNL4 ss469415590 与 HCV(+)/HIV(-)个体对干扰素/利巴韦林治疗的反应强烈相关，但与 HIV(+)/HCV(+)患者无关。因此，IFNL4 变异的影响可能在 HIV(+)和 HIV(-)患者中有所不同。
